Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
DUO-E Investigators
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial'. Together they form a unique fingerprint.
Medicine and Dentistry
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science